Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: DPP-IVi, Other, SGLT2i Jul 21 | 2021Leqvio PDUFA Date Disclosed; Verquvo EC approval; Ph1b Trial to Delay the Onset or Progression of T1DM Meets Primary Endpoint; Novartis and J&J Q2 '21 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Glucagon, Insulin Delivery, Other Jul 20 | 2021Ascensia Launches Patient Assistance Program for Eversense; Dario Digital Health Contract; Xeris EU Distribution Agreement for Ogluo; Medtronic Extended Wear Infusion Set 510(k) Clearance; Nimium Partnership for G3PP Activator Development; TempraMed Launches Insulin Cooler CapPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Other, SGLT2i Jul 19 | 2021Removal of Forxiga T1DM Indication? Generic Sitagliptin Up for Opinion?; July 19-22 CHMP AgendaPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jul 16 | 2021GSK Releases Positive Dapro Topline Results Day After Negative Roxa Adcom; Dexcom Cleared for Third-party Integration; New Medtronic Klue Trial ObservedPurchase Blast
$599
Posted in: Other Jul 15 | 2021Roxa Adcom Votes Overwhelmingly Against Approval in NDD (1-13) and DD (2-12)Purchase Blast
$599
Posted in: Other Jul 13 | 2021Roxa Adcom Docs Released: FDA Mixed on Risk-BenefitPurchase Blast$599
Posted in: Other, SGLT2i Jul 12 | 2021Novo Buys Cardiomyopathy Asset From Prothena; Teplizumab Receives UK Innovation Passport; Poxel Reorganizes Strategic Direction; Dario Announces New Employer Contracts; New Generic Sitagliptin Received Tentative ApprovalPurchase Blast
$599
Posted in: Glucose Monitoring Jul 07 | 2021CGM Patent-infringement Suits: Dexcom Sues Abbott; Abbott Sues DexcomPurchase Blast
$599
Posted in: Other Jul 06 | 2021Novartis Resubmits Inclisiran NDA; Provention Bio Receives CRL for TeplizumabPurchase Blast
$599
Posted in: SGLT2i Jul 06 | 2021Jardiance Positive HFpEF Topline Results (EMPEROR-Preserved)Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Jul 01 | 2021Why Lilly Will Terminate GGG; Lilly ADA 2021 Investor UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other, SGLT2i Jun 29 | 2021ADA 2021 Key Press Releases (June 29)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, SGLT2i Jun 28 | 2021ADA 2021 Key Press Releases (June 28)Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Jun 28 | 2021Novo Dual Agonist T2DM Intentions Disclosed at ADA Investor Event; Lilly Could Pursue Hypo Claim vs. Degludec in QW Basal Ph3Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jun 27 | 2021ADA 2021 Key Press Releases (June 27)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 25 | 2021ADA 2021 Key Press Releases (June 25)Purchase Blast